Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.


BACKGROUND The prognosis of patients with systemic light chain (AL) amyloidosis, particularly cardiac, is poor. Treatments have been derived from multiple myeloma, but there are few studies that use triplet regimens in AL amyloidosis because of concern of greater toxicity than seen in myeloma. PATIENTS AND METHODS We conducted a retrospective review of… (More)
DOI: 10.1016/j.clml.2012.09.011


  • Presentations referencing similar topics